Treatment with 213Bi-rituximab was more effective in severe combined immunodeficient (SCID) mice bearing Burkitt lymphoma (Raji) than 213Bi or 213Bi anti-human epidermal growth factor receptor 2 (HER2)/neu [47]. This evidence concerns the gene ERBB2 and Burkitt lymphoma.